Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PGK1 | P00558 | 1/20 | 1.00 |
| ▸ | PGK2 | P07205 | 1/20 | 1.00 |
| ▸ | PGD | P52209 | 3/20 | 0.63 |
| ▸ | MPI | P34949 | 1/20 | 0.47 |
| ▸ | OR51E2 | Q9H255 | 1/20 | 0.40 |
| ▸ | LPAR5 | Q9H1C0 | 2/20 | 0.39 |
| ▸ | LPAR6 | P43657 | 1/20 | 0.39 |
| ▸ | LPAR1 | Q92633 | 1/20 | 0.39 |
| ▸ | LPAR4 | Q99677 | 1/20 | 0.39 |
| ▸ | LPAR2 | Q9HBW0 | 1/20 | 0.39 |
| ▸ | LPAR3 | Q9UBY5 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| 3-Phosphoglyceric Acid SCHEMBL30428419 | 1.00 | PGK1 (1.00) | PGK1PGK2PGDMPIOR51E2 | |
| 3-Phosphoglyceric Acid SCHEMBL27483 | 1.00 | PGK1 (1.00) | PGK1PGK2PGDMPIOR51E2 | |
| 3-Phosphoglyceric Acid SCHEMBL27482 | 1.00 | PGK1 (1.00) | PGK1PGK2PGDMPIOR51E2 | |
| 3-Phosphoglyceric Acid SCHEMBL8006738 | 0.90 | PGK1 (0.81) | PGK1PGK2PGDMPISMN1; SMN2 | |
| SCHEMBL1812894 | 0.83 | PGK1 (0.70) | PGK1PGK2PGDLPAR1LPAR3 | |
| SCHEMBL21724798 | 0.82 | PGK1 (0.69) | PGK1PGK2PGDMPILPAR5 | |
| SCHEMBL2510085 | 0.82 | PGK1 (0.69) | PGK1PGK2PGDMPILPAR5 | |
| SCHEMBL29357297 | 0.81 | PGK1 (0.68) | PGK1PGK2PGDMPILPAR5 | |
| 3-Phosphoglyceric Acid SCHEMBL15019970 | 0.80 | PGK1 (0.64) | PGK1PGK2PGD | |
| SCHEMBL704407 | 0.79 | PGK1 (0.65) | PGK1PGK2PGDMPILPAR5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 350 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260063623-A1 | METHODS OF ASSESSING METABOLIC FLUX | UNIV MICHIGAN REGENTS (US) | 2026-03-05 | — | — | US | claimed |
| US-20260035705-A1 | ENGINEERED MICROORGANISMS WITH G3P ->3PG ENZYME AND/OR FRUCTOSE-1,6-BISPHOSPHATASE INCLUDING THOSE HAVING SYNTHETIC OR ENHANCED METHYLOTROPHY | AGAIN BIO APS (DK) | 2026-02-05 | — | — | US | claimed |
| EP-4602365-A2 | METHODS OF ASSESSING METABOLIC FLUX | The Regents of The University of Michigan (US) | 2025-08-20 | — | — | EP | claimed |
| EP-4537111-A2 | MULTI-OMICS ASSESSMENT | Prognomiq Inc (US) | 2025-04-16 | — | — | EP | claimed |
| WO-2025072741-A1 | PRESERVATIVES FOR MOLECULAR SAMPLE ANALYSIS WITH SAMPLE COLLECTION DEVICES | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2025-04-03 | — | — | WO | claimed |
| US-12234463-B2 | Engineered microorganisms with G3P → 3PG enzyme and/or fructose-1,6-bisphosphatase including those having synthetic or enhanced methylotrophy | GENOMATICA, INC. (US) | 2025-02-25 | — | — | US | claimed |
| WO-2025016307-A1 | HEALTH HOMEOSTASIS MODEL, ELASTIC HOMEOSTASIS MODEL, AND USAGE METHOD THEREFOR | 汤臣倍健股份有限公司 | 2025-01-23 | — | — | WO | claimed |
| EP-4457513-A1 | COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING CHRONIC KIDNEY DISEASE | Société des Produits Nestlé S.A. (CH) | 2024-11-06 | — | — | EP | claimed |
| WO-2024206366-A2 | GENETICALLY ENCODED SYSTEM FOR QUANTIFYING RUBISCO ACTIVITY IN CATALYZING CARBON FIXATION | THE SCRIPPS RESEARCH INSTITUTE (US) | 2024-10-03 | — | — | WO | claimed |
| EP-4437319-A1 | METHODS AND COMPOSITIONS FOR ANALYTE QUANTIFICATION | Matterworks Inc (US) | 2024-10-02 | — | — | EP | claimed |
| EP-4141122-A2 | CARBON-NEUTRAL AND CARBON-POSITIVE PHOTORESPIRATION BYPASS ROUTES SUPPORTING HIGHER PHOTOSYNTHETIC RATE AND YIELD | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2023-03-01 | — | — | EP | claimed |
| WO-2023015285-A1 | MICROORGANISMS AND METHODS FOR IMPROVED BIOLOGICAL PRODUCTION OF ETHYLENE GLYCOL | LANZATECH, INC. (US) | 2023-02-09 | — | — | WO | claimed |
| US-20230015215-A1 | EVALUATION METHOD OF DIFFERENTIATION STATE OF CELLS, AND CELL CULTURE SYSTEM | HITACHI HIGH-TECH CORPORATION (JP) | 2023-01-19 | — | — | US | claimed |
| EP-4092129-A1 | EVALUATION METHOD OF DIFFERENTIATION STATE OF CELLS, AND CELL CULTURE SYSTEM | Hitachi High-Tech Corporation (JP) | 2022-11-23 | — | — | EP | claimed |
| US-20220348897-A1 | GENETICALLY OPTIMISED MICROORGANISM FOR PRODUCING MOLECULES OF INTEREST | EPPEN EUROPE (FR) | 2022-11-03 | — | — | US | claimed |
| CN-114846151-A | Method for evaluating cell differentiation state and cell culture system | 株式会社日立高新技术 | 2022-08-02 | — | — | CN | claimed |
| US-20220177895-A1 | ENGINEERED MICROORGANISMS WITH G3P -> 3PG ENZYME AND/OR FRUCTOSE-1,6-BISPHOSPHATASE INCLUDING THOSE HAVING SYNTHETIC OR ENHANCED METHYLOTROPHY | AGAIN BIO APS (DK) | 2022-06-09 | — | — | US | claimed |
| EP-3946054-A1 | COMPOSITIONS, METHODS AND SYSTEMS FOR PROTEIN CORONA ANALYSIS FROM BIOFLUIDS AND USES THEREOF | Seer, Inc. (US) | 2022-02-09 | — | — | EP | claimed |
| US-20160282351-A1 | SALIVARY BIOMARKERS FOR CANCERS, METHODS AND DEVICES FOR ASSAYING THE SAME, AND METHODS FOR DETERMINING SALIVARY BIOMARKERS FOR CANCERS | SALIVATECH CO., LTD. (JP) | 2016-09-29 | — | — | US | claimed |
| EP-3064940-A1 | SALIVARY BIOMARKER FOR CANCER, METHOD AND DEVICE FOR ASSAYING SAME, AND METHOD FOR DETERMINING SALIVARY BIOMARKER FOR CANCER | Salivatech Co., Ltd. (JP) | 2016-09-07 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260063623-A1 | METHODS OF ASSESSING METABOLIC FLUX | PC, SLC2A1, SLC2A4 | PGK1 199/4885PGK2 329/4885PGD 19/4885 |
| US-20260035705-A1 | ENGINEERED MICROORGANISMS WITH G3P ->3PG ENZYME AND/OR FRUCTOSE-1,6-BISPHOSPHATASE INCLUDING THOSE HAVING SYNTHETIC OR ENHANCED METHYLOTROPHY | ME1, FBP1, ME3 | PGK1 44/4885PGK2 75/4885PGD 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.